A5060029100- Multiple and Secondary Primary Cancers
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Viral Infectious Diseases and Gene Expression in Insects
- Advanced Breast Cancer Therapies
- Histone Deacetylase Inhibitors Research
- Bladder and Urothelial Cancer Treatments
- Protein Degradation and Inhibitors
- Chemotherapy-induced cardiotoxicity and mitigation
- Colorectal Cancer Screening and Detection
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
IQVIA (United Kingdom)
2020-2024
e23297 Background: Risks and benefits associated with use of anticoagulants (ACs) in cancer patients should be carefully assessed due to an increased risk both thrombotic recurrences bleeding events. Vitamin K antagonists (AVK) have been the most used ACs for atrial fibrillation venous thromboembolism many years. Low molecular weight heparins (LMWH) direct oral (DOACs) are preferred over AVK thrombosis. To better define current scenario we propose market research data describe treatment...
e19327 Background: Micro-Satellite Instability (MSI) or DNA Mismatch Repair (MMR) is an established prognostic test associated with response to chemotherapies in Lynch Syndrome, colorectal cancer and other indications. Recently, MSI/MMR status has been shown predict immune checkpoint inhibitors (CPI). Pembrolizumab approved the USA for MSI-high mismatch repair deficient patients all A similar approval not obtained EU. This data research project examined testing Europe its possible...
To explore the incorporation of novel agents in first-line setting for acute myeloid leukemia patients.